Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction

Author(s): Mohamed Salama, Ti-Fei Yuan, Sergio Machado, Eric Murillo-Rodriguez, Jose A. Vega, Manuel Menendez-Gonzalez, Antonio E. Nardi, Oscar Arias-Carrion

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 12 , Issue 5 , 2013

Become EABM
Become Reviewer


Coenzyme Q10 (CoQ10) is critical for the cell power supply in mitochondria. CoQ10 shuttles electrons from complexes I and II to complex III, and can be anti-oxdiative. Neurons require high energy for synaptic transmission and therefore the mitochondria dysfunction often leads to severe neuronal degeneration, as observed in many neurological disorders. CoQ10 supplementation has been widely used to treat aging, stroke, neuromuscular diseases, Alzheimer's disease, Parkinson’s disease, progressive supranuclear palsy, autosomal recessive cerebellar ataxias, Huntington’s disease and amyotrophic lateral sclerosis. Here we discuss a large number of preclinical and clinical trials for CoQ10 to elucidate the mechanisms underlying CoQ10 therapy. The rational applications as a therapeutic agent in neurological disorders are discussed.

Keywords: Coenzyme Q10, mitochondrial respiratory chain, neurological disorders, rational therapeutic approaches, ATP.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [641 - 664]
Pages: 24
DOI: 10.2174/18715273113129990071
Price: $65

Article Metrics

PDF: 44